© 2005 Oxford University Press
COMMENTARY |
Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT)
Affiliation of authors: The University of Texas M.D. Anderson Cancer Center, Houston, TX (SML, AH, EDC); Southwest Oncology Group Statistical Center, Seattle, WA (PJG, CMM, JJC); Cleveland Clinic Foundation, Cleveland, OH (EAK); National Cancer Institute, Bethesda, MD (HLP, DA, PRT, LMM, LGF); University of Texas Health Science Center at San Antonio, San Antonio, TX (IMT); Fred Hutchinson Cancer Research Center, Seattle, WA (ARK, JLS); Columbia University College of Physicians and Surgeons, New York, NY (RMS); University of Washington, Seattle, WA (JLP); Louisiana State University Health Science Center, New Orleans, LA (SMT); Boston VA Healthcare System, Boston, MA (JMG); Canadian Urologic Oncology Group, Toronto, ON, Canada (NEF); North Central Cancer Treatment Group, Rochester, MN (MML); Cancer and Leukemia Group B, Chicago, IL (PJW); Radiation Therapy Oncology Group, Philadelphia, PA (FRK); Eastern Cooperative Oncology Group, Brookline, MA (DDK); Wake Forest University School of Medicine, Winston-Salem, NC (GGS); Southwest Oncology Group Operations Office, San Antonio, TX (CAC)
Correspondence to: Scott M. Lippman, MD, M. D. Anderson Cancer Center, Department of Clinical Cancer Prevention, Rm. HMB 11.192, Box 236, 1515 Holcombe Blvd., Houston, TX 77030-4009 (e-mail: slippman{at}mdanderson.org)
Prostate cancer continues to be a major health threat, especially among African American men. The Selenium and Vitamin E Cancer Prevention Trial (SELECT), which opened on July 25, 2001, was planned to study possible agents for the prevention of prostate cancer in a population of 32 400 men in the United States, including Puerto Rico, and Canada. SELECT is a phase III randomized, placebo-controlled trial of selenium (200 µg/day from L-selenomethionine) and/or vitamin E (400 IU/day of all rac 
-tocopheryl acetate) supplementation for a minimum of 7 years (maximum of 12 years) in non–African American men at least 55 years of age and African American men at least 50 years of age. SELECT is a large, simple trial that conforms as closely as possible with community standards of care. This commentary discusses the design problems the SELECT investigators had to resolve in developing the trial, including the role of prostate cancer screening, the best forms and doses of the study agents, and estimation of the event (prostate cancer) rate of men on the placebo arm.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  W. Demark-Wahnefried, S. L George, B. R Switzer, D. C Snyder, J. F Madden, T. J Polascik, M. T Ruffin IV, and R. T Vollmer Overcoming challenges in designing and implementing a phase II randomized controlled trial using a presurgical model to test a dietary intervention in prostate cancer Clinical Trials, June 1, 2008; 5(3): 262 - 272. [Abstract] [PDF]
|
|
|
|
|
|
C. L Meinert Long-term drug prevention trials Clinical Trials, April 1, 2008; 5(2): 168 - 176. [Abstract] [PDF]
|
|
|
|
 |
|
 C. Atkinson, K. M Newton, E. J A. Bowles, M. Yong, and J. W Lampe Demographic, anthropometric, and lifestyle factors and dietary intakes in relation to daidzein-metabolizing phenotypes among premenopausal women in the United States Am. J. Clinical Nutrition, March 1, 2008; 87(3): 679 - 687. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Hu, G.-x. Li, L. Wang, J. Watts, G. F. Combs Jr., and J. Lu Methylseleninic Acid Enhances Taxane Drug Efficacy against Human Prostate Cancer and Down-Regulates Antiapoptotic Proteins Bcl-XL and Survivin Clin. Cancer Res., February 15, 2008; 14(4): 1150 - 1158. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. N. Syed, N. Khan, F. Afaq, and H. Mukhtar Chemoprevention of Prostate Cancer through Dietary Agents: Progress and Promise Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2193 - 2203. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Sedjo, T. Byers, E. Barrera Jr., C. Cohen, E. T. H. Fontham, L. A. Newman, C. D. Runowicz, A. G. Thorson, M. J. Thun, E. Ward, et al. A Midpoint Assessment of the American Cancer Society Challenge Goal to Decrease Cancer Incidence by 25% Between 1992 and 2015 CA Cancer J Clin, November 1, 2007; 57(6): 326 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Waters, S. Shen, H. Xu, S. S. Kengeri, D. M. Cooley, E. C. Chiang, Y. Chen, D. Schlittler, C. Oteham, G. F. Combs Jr., et al. Noninvasive Prediction of Prostatic DNA Damage by Oxidative Stress Challenge of Peripheral Blood Lymphocytes Cancer Epidemiol. Biomarkers Prev., September 1, 2007; 16(9): 1906 - 1910. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Gray, J. T. Mao, E. Szabo, M. Kelley, J. Kurie, and G. Bepler Lung Cancer Chemoprevention: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 56S - 68S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Stranges, J. R. Marshall, R. Natarajan, R. P. Donahue, M. Trevisan, G. F. Combs, F. P. Cappuccio, A. Ceriello, and M. E. Reid Effects of Long-Term Selenium Supplementation on the Incidence of Type 2 Diabetes: A Randomized Trial Ann Intern Med, August 21, 2007; 147(4): 217 - 223. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Bleys, A. Navas-Acien, and E. Guallar Selenium and Diabetes: More Bad News for Supplements Ann Intern Med, August 21, 2007; 147(4): 271 - 272. [Full Text] [PDF]
|
|
|
|
|
|
S. J. Weinstein, M. E. Wright, K. A. Lawson, K. Snyder, S. Mannisto, P. R. Taylor, J. Virtamo, and D. Albanes Serum and Dietary Vitamin E in Relation to Prostate Cancer Risk Cancer Epidemiol. Biomarkers Prev., June 1, 2007; 16(6): 1253 - 1259. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Bleys, A. Navas-Acien, and E. Guallar Serum Selenium and Diabetes in U.S. Adults Diabetes Care, April 1, 2007; 30(4): 829 - 834. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. G. Christen, J. E. Manson, R. J. Glynn, J. M. Gaziano, E. Y. Chew, J. E. Buring, and C. H. Hennekens Beta Carotene Supplementation and Age-Related Maculopathy in a Randomized Trial of US Physicians Arch Ophthalmol, March 1, 2007; 125(3): 333 - 339. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Peters, C. B Foster, N. Chatterjee, A. Schatzkin, D. Reding, G. L Andriole, E D. Crawford, S. Sturup, S. J Chanock, and R. B Hayes Serum selenium and risk of prostate cancer--a nested case-control study Am. J. Clinical Nutrition, January 1, 2007; 85(1): 209 - 217. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. T. Mayne and B. Cartmel Chemoprevention of Second Cancers Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2033 - 2037. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Flores-Mateo, A. Navas-Acien, R. Pastor-Barriuso, and E. Guallar Selenium and coronary heart disease: a meta-analysis. Am. J. Clinical Nutrition, October 1, 2006; 84(4): 762 - 773. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Kelloff, S. M. Lippman, A. J. Dannenberg, C. C. Sigman, H. L. Pearce, B. J. Reid, E. Szabo, V. C. Jordan, M. R. Spitz, G. B. Mills, et al. Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer--A Plan to Move Forward Clin. Cancer Res., June 15, 2006; 12(12): 3661 - 3697. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Diwadkar-Navsariwala, G. S. Prins, S. M. Swanson, L. A. Birch, V. H. Ray, S. Hedayat, D. L. Lantvit, and A. M. Diamond Selenoprotein deficiency accelerates prostate carcinogenesis in a transgenic model PNAS, May 23, 2006; 103(21): 8179 - 8184. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Kamangar, G. M. Dores, and W. F. Anderson Patterns of Cancer Incidence, Mortality, and Prevalence Across Five Continents: Defining Priorities to Reduce Cancer Disparities in Different Geographic Regions of the World J. Clin. Oncol., May 10, 2006; 24(14): 2137 - 2150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. F. Burk, B. K. Norsworthy, K. E. Hill, A. K. Motley, and D. W. Byrne Effects of chemical form of selenium on plasma biomarkers in a high-dose human supplementation trial. Cancer Epidemiol. Biomarkers Prev., April 1, 2006; 15(4): 804 - 810. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Lippman and J. J. Lee Reducing the "Risk" of Chemoprevention: Defining and Targeting High Risk--2005 AACR Cancer Research and Prevention Foundation Award Lecture. Cancer Res., March 15, 2006; 66(6): 2893 - 2903. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I-M. Lee, J. M. Gaziano, and J. E. Buring Vitamin E in the prevention of prostate cancer: where are we today? J Natl Cancer Inst, February 15, 2006; 98(4): 225 - 227. [Full Text] [PDF]
|
|
|
|
|
|
V. A. Kirsh, R. B. Hayes, S. T. Mayne, N. Chatterjee, A. F. Subar, L. B. Dixon, D. Albanes, G. L. Andriole, D. A. Urban, and U. Peters Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk. J Natl Cancer Inst, February 15, 2006; 98(4): 245 - 254. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Cai, L.-N. Mu, H. Lu, Q.-Y. Lu, N.-C. Y. You, S.-Z. Yu, A. D. Le, J. Zhao, X.-F. Zhou, J. Marshall, et al. Dietary Selenium Intake and Genetic Polymorphisms of the GSTP1 and p53 Genes on the Risk of Esophageal Squamous Cell Carcinoma. Cancer Epidemiol. Biomarkers Prev., February 1, 2006; 15(2): 294 - 300. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Hu, R. V. Benya, R. E. Carroll, and A. M. Diamond Allelic Loss of the Gene for the GPX1 Selenium-Containing Protein Is a Common Event in Cancer J. Nutr., December 1, 2005; 135(12): 3021S - 3024S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Chan, P. H. Gann, and E. L. Giovannucci Role of Diet in Prostate Cancer Development and Progression J. Clin. Oncol., November 10, 2005; 23(32): 8152 - 8160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. M. Thompson, C. M. Tangen, E. A. Klein, and S. M. Lippman Phase III Prostate Cancer Prevention Trials: Are the Costs Justified? J. Clin. Oncol., November 10, 2005; 23(32): 8161 - 8164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. T. Mayne and S. M. Lippman Cigarettes: A Smoking Gun in Cancer Chemoprevention J Natl Cancer Inst, September 21, 2005; 97(18): 1319 - 1321. [Full Text] [PDF]
|
|
|
|
|
|
W. McCaskill-Stevens, M. M. McKinney, C. G. Whitman, and L. M. Minasian Increasing Minority Participation in Cancer Clinical Trials: The Minority-Based Community Clinical Oncology Program Experience J. Clin. Oncol., August 1, 2005; 23(22): 5247 - 5254. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. R. Hirsch and S. M. Lippman Advances in the Biology of Lung Cancer Chemoprevention J. Clin. Oncol., May 10, 2005; 23(14): 3186 - 3197. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. G. Brown and J. Crowley Is There Any Hope for Vitamin E? JAMA, March 16, 2005; 293(11): 1387 - 1390. [Full Text] [PDF]
|
|